L'intérêt à découvert pour AIM ETF Products Trust AllianzIM U.S. Large Cap 6 Month Buffer10 Feb/Aug ETF donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de AIM ETF Products Trust AllianzIM U.S. Large Cap 6 Month Buffer10 Feb/Aug ETF. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

AIM ETF Products Trust AllianzIM U.S. Large Cap 6 Month Buffer10 Feb/Aug ETF (ARCA:SIXF), Rapport sur les intérêts à découvert

The Fund pursues a buffered strategy that seeks to match the share price returns of the SPDR S&P 500 ETF Trust (the Underlying ETF) (i.e., the market price returns of the Underlying ETF), at the end of a specified one-year period, from February 1 to January 31, as described below (the Outcome Period), subject to an upside maximum percentage return (the Cap) and a downside buffer against the first 10% of losses (the Buffer).

AllianzIM US Large Cap 6 Month Buffer10 Feb/Aug ETF

AIM ETF Products Trust AllianzIM U.S. Large Cap 6 Month Buffer10 Feb/Aug ETF

WIIM

$BTC

$ETH

Cryptocurrencies are trading lower amid overall market weakness on US consumer concerns and trade war uncertainty, which could be weighing on risk sentiment.

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday.
The Dow traded up 0.46% to 43,661.51 while the NASDAQ fell 1.07% to 19,080.23. The S&amp;P 500 also fell, dropping, 0.29% to 5,965.92.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43909562/top-2-industrials-stocks-that-are-set-to-fly-this-quarter">Top 2 Industrials Stocks That Are Set To Fly This Quarter</a>
Leading and Lagging Sectors Consumer staples shares jumped by 1.3% on Tuesday.
In trading on Tuesday, energy shares fell by 1.3%.
Top Headline
Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) shares gained around 2.5% on Tuesday following better-than-expected quarterly results.
The company reported fourth-quarter adjusted earnings per share of 58 cents, beating the street view of 57 cents. Quarterly sales of $4.07 billion (+5.2% year over year), outpaced the analyst consensus estimate of $4.02 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares shot up 217% to $1.19 after the company announced that Eli Lilly is set to acquire its FXR program, including FXR314.</li>
<li>Shares of Wah Fu Education Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>)got a boost, surging 84% to $3.2950 after the company announced it will integrate DeepSeek to drive AI-based education innovation and long-term growth strategies.</li>
<li>AdaptHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) shares were also up, gaining 24% to $10.57 after the company reported better-than-expected fourth-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares dropped 30% to $9.11 after the company reported worse-than-expected quarterly financial results.</li>
<li>Shares of Hims &amp; Hers Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) were down 22% to $40.02 after the company reported fourth-quarter financial results.</li>
<li>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) was down, falling 19% to $70.52 after the company issued FY25 EPS below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 2.4% to $69.02 while gold traded down 1.3% at $2,924.50.
Silver traded down 2% to $31.95 on Tuesday, while copper rose 0.7% to $4.5470.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.15%, Germany's DAX 40 fell 0.07% and France's CAC 40 fell 0.49%. Spain's IBEX 35 Index rose 0.80%, while London's FTSE 100 rose 0.11%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei falling 1.39%, China's Shanghai Composite Index falling 0.80%, Hong Kong's Hang Seng Index dipping 1.32% and India's BSE Sensex gaining 0.20%.
Economics
<ul>
<li>The Dallas Fed&#8217;s general business activity index for Texas's service sector fell by 2.8 points to a reading of 4.6 in February.</li>
<li>The S&amp;P CoreLogic Case-Shiller 20-city home price index rose by 4.5% year-over-year in December compared to 4.3% in the previous month.</li>
<li>The FHFA house prices index increased by 0.4% in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AHCO

BTDR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ONVO

WAFU

Dow Surges 200 Points; Keurig Dr Pepper Posts Upbeat Earnings

SONO

Sonos shares are trading higher after the company announced a $150 million stock repurchase program.

Yatsen Holding shares are trading lower. The company reported Q4 financial results.

In the current market session, Phinia Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) stock price is at $50.30, after a 0.81% drop. However, over the past month, the company's stock went up by 0.14%, and in the past year, by 50.18%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1740514523_0.png" alt="Past Year Chart" />

<h3>Phinia P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Phinia has a better P/E ratio of 28.81 than the aggregate P/E ratio of 22.04 of the Automobile Components industry. Ideally, one might believe that Phinia Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740514523_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

PHIN

Price Over Earnings Overview: Phinia

American Finl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) has outperformed the market over the past 20 years by 1.1% on an annualized basis producing an average annual return of 9.31%. Currently, American Finl Gr has a market capitalization of $10.16 billion. 
Buying $100 In AFG: If an investor had bought $100 of AFG stock 20 years ago, it would be worth $603.64 today based on a price of $121.00 for AFG at the time of writing.
<h3>American Finl Gr's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740514510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

HLIO

Helios Technologies shares are trading higher after the company reported better-than-expected Q4 revenue results and announced approval for a $100 million share repurchase program

GDS Holdings shares are trading lower after RBC Capital downgraded its rating on the stock from outperform to perform despite raising its price target from $26 to $37.

Helix Energy Solutions shares are trading higher after the company reported better-than-expected Q4 financial results.

UFPT

UFP Technologies shares are trading higher after the company reported better-than-expected Q4 financial results.

XMTR

Xometry shares are trading lower. The company reported Q4 financial results.

CMTG

Claros Mortgage Trust shares are trading lower after Wells Fargo and UBS cut their respective price targets on the stock.

Methode Electronics shares are trading higher after Sidoti & Co. upgraded the stock from Neutral to Buy and announced a price target of $14.

ADUS

Addus HomeCare shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

Obsidian Energy shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

AORT

Artivion shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS and revenue estimates. Additionally, Needham and Stifel cut their respective price targets on the stock.

MYGN

Myriad Genetics shares are trading lower following a Q4 revenue miss and FY25 revenue guidance below estimates. The stock may also be trading on weakness after it announced it will face cost restructuring following UnitedHealthcare's decision to end Genesight coverage. Additionally, UBS and Raymond James cut their respective price targets on the stock.

Financial giants have made a conspicuous bullish move on Starbucks. Our analysis of options history for Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) revealed 30 unusual trades.
Delving into the details, we found 53% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $659,935, and 16 were calls, valued at $732,423.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $145.0 for Starbucks during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Starbucks's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Starbucks's whale activity within a strike price range from $95.0 to $145.0 in the last 30 days. 
<h3>Starbucks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740513715_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$20.45</td>
<td>$20.35</td>
<td>$20.35</td>
<td>$100.00</td>
<td>$122.1K</td>
<td>0</td>
<td align="right">60</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$28.0</td>
<td>$26.4</td>
<td>$26.8</td>
<td>$135.00</td>
<td>$101.8K</td>
<td>0</td>
<td align="right">38</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$130.00</td>
<td>$95.4K</td>
<td>1.2K</td>
<td align="right">299</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$23.4</td>
<td>$23.05</td>
<td>$23.35</td>
<td>$130.00</td>
<td>$81.7K</td>
<td>71</td>
<td align="right">105</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$18.0</td>
<td>$15.35</td>
<td>$15.6</td>
<td>$115.00</td>
<td>$78.0K</td>
<td>1.0K</td>
<td align="right">54</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries as of the end of fiscal 2024. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
In light of the recent options history for Starbucks, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Starbucks</h3>
<ul>
<li>With a volume of 7,121,246, the price of SBUX is up 1.48% at $114.86. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 63 days.</li>
</ul>
<h3>What The Experts Say On Starbucks</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $114.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Neutral rating on Starbucks, maintaining a target price of $105. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Starbucks, targeting a price of $115. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $115. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Starbucks with a target price of $114. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Starbucks with a target price of $125. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

SBUX

A Closer Look at Starbucks's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bullish stance on Viking Therapeutics.
Looking at options history for Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 69% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $453,915 and 7, calls, for a total amount of $500,554.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $100.0 for Viking Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $20.0 to $100.0 in the last 30 days. 
<h3>Viking Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740513710_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$7.2</td>
<td>$35.00</td>
<td>$160.5K</td>
<td>1.3K</td>
<td>297</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.43</td>
<td>$1.42</td>
<td>$1.42</td>
<td>$25.00</td>
<td>$142.1K</td>
<td>216</td>
<td>1.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.85</td>
<td>$1.43</td>
<td>$1.44</td>
<td>$25.00</td>
<td>$141.6K</td>
<td>216</td>
<td>2.6K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.05</td>
<td>$0.99</td>
<td>$1.05</td>
<td>$35.00</td>
<td>$105.0K</td>
<td>6.0K</td>
<td>199</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.85</td>
<td>$1.46</td>
<td>$1.46</td>
<td>$25.00</td>
<td>$57.1K</td>
<td>216</td>
<td>2.6K</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Having examined the options trading patterns of Viking Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Viking Therapeutics's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,281,250, the price of VKTX is down by -3.94%, reaching $28.05.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 57 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $81.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Maxim Group has decided to maintain their Buy rating on Viking Therapeutics, which currently sits at a price target of $70. 
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $38. 
&#x2A; An analyst from Raymond James has decided to maintain their Strong Buy rating on Viking Therapeutics, which currently sits at a price target of $125. 
&#x2A; An analyst from Scotiabank downgraded its action to Sector Outperform with a price target of $102. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Viking Therapeutics, maintaining a target price of $71. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

VKTX

A Closer Look at Viking Therapeutics's Options Market Dynamics

Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.25, with a high estimate of $36.00 and a low estimate of $31.00. A 0.75% drop is evident in the current average compared to the previous average price target of $33.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740513705_0_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Anglogold Ashanti's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Josh Wolfson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Patrick Jones</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Josh Wolfson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Anglogold Ashanti. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Anglogold Ashanti compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Anglogold Ashanti's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Anglogold Ashanti's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Anglogold Ashanti analyst ratings.</a>
<h2>Discovering Anglogold Ashanti: A Closer Look</h2>
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
<h3>Financial Milestones: Anglogold Ashanti's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Anglogold Ashanti's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 17.37%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Anglogold Ashanti's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 26.86%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Anglogold Ashanti's ROE stands out, surpassing industry averages. With an impressive ROE of 8.74%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.32%, the company showcases effective utilization of assets.
Debt Management: Anglogold Ashanti's debt-to-equity ratio stands notably higher than the industry average, reaching 0.32. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 4 Analyst Ratings Have To Say About Anglogold Ashanti

AllianzIM U.S. Large Cap 6 Month Buffer10 Feb/Aug ETF

Comments

AIM ETF Products Trust AllianzIM U.S. Large Cap 6 Month Buffer10 Feb/Aug ETF

Intérêt court

AIM ETF Products Trust AllianzIM U.S. Large Cap 6 Month Buffer10 Feb/Aug ETF (ARCA:SIXF), Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL